The Irish government has signed landmark new Framework Agreements on the Supply and Pricing of Medicines with the Irish Pharmaceutical Healthcare Association (IPHA) and Medicines for Ireland (MFI). These agreements introduce a structured pathway designed to dramatically reduce the time patients wait for access to innovative medicines.
Addressing Historical Access Delays
While previous legislation established a nominal 180-day target for reimbursement decisions following European regulatory approval, the State has historically struggled to meet this deadline, leaving patients waiting significantly longer for life-saving therapies. These new frameworks finally operationalize this commitment, outlining a concrete roadmap to achieve consistent 180-day turnaround times by the first quarter of 2029.
Key Objectives of the Agreements
The new frameworks, which replace the 2021-2025 agreements, will remain in effect until the end of 2029. Key objectives include:
- Speeding Up Access: Implementing process reforms to ensure faster availability of innovative drugs for Irish patients.
- Supply Chain Security: Strengthening the resilience of medicine supplies to mitigate the risk of national shortages.
- Encouraging Generics and Biosimilars: Promoting the early launch of off-patent and biosimilar medicines to create financial headroom within the health service.
- Financial Sustainability: Generating significant savings that can be reinvested directly back into the healthcare system to fund new, high-cost therapies.
Industry leaders have welcomed the agreements, noting that greater certainty and consistency in the pharmaceutical sector are essential amid ongoing international policy shifts. By aligning state processes with the needs of both patients and innovators, Ireland is taking a critical step forward in ensuring equitable and timely healthcare access.
